Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Single Agent Study of Selinexor (KPT-330) in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Prior Therapy With Abiraterone and/or Enzalutamide

NCT02215161 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT02215161
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02215161 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Single Agent Study of Selinexor (KPT-330) in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Prior Therapy With Abiraterone and/or Enzalutamide
Lead sponsor
University of California, San Francisco
Phase
Phase 2
Overall status
Terminated
Start date
September 2, 2014
Completion date
April 2, 2018
Enrollment
14 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

castration levels of testosterone, hormone-resistant prostate cancer, metastatic prostate carcinoma in the soft tissue, prostate carcinoma metastatic in the bone, psa progression, stage iv prostate adenocarcinoma ajcc v7